Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017:2017:1839809.
doi: 10.1155/2017/1839809. Epub 2017 Mar 13.

Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective

Affiliations
Review

Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective

Rui Xue et al. J Diabetes Res. 2017.

Abstract

Diabetic nephropathy (DN) is the most serious microvascular complication of diabetes and the largest single cause of end-stage renal disease (ESRD) in many developed countries. DN is also associated with an increased cardiovascular mortality. It occurs as a result of interaction between both genetic and environmental factors. Hyperglycemia, hypertension, and genetic predisposition are the major risk factors. However, the exact mechanisms of DN are unclear. Despite the benefits derived from strict control of glucose and blood pressure, as well as inhibition of renin-angiotensin-aldosterone system, many patients continue to enter into ESRD. Thus, there is urgent need for improving mechanistic understanding of DN and then developing new and effective therapeutic approaches to delay the progression of DN. This review focuses on recent progress and future perspective about mechanistic insight and management of DN. Some preclinical relevant studies are highlighted and new perspectives of traditional Chinese medicine (TCM) for delaying DN progression are discussed in detail. These findings strengthen the therapeutic rationale for TCM in the treatment of DN and also provide new insights into the development of novel drugs for the prevention of DN. However, feasibility and safety of these therapeutic approaches and the clinical applicability of TCM in human DN need to be further investigated.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interests relevant to this article was reported.

References

    1. Chopra B., Sureshkumar K. K. Co-stimulatory blockade with belatacept in kidney transplantation. Expert Opinion on Biological Therapy. 2014;14(5):563–567. doi: 10.1517/14712598.2014.896332. - DOI - PubMed
    1. Brenneman J., Hill J., Pullen S. Emerging therapeutics for the treatment of diabetic nephropathy. Bioorganic and Medicinal Chemistry Letters. 2016;26(18):4394–4402. doi: 10.1016/j.bmcl.2016.07.079. - DOI - PubMed
    1. Saran R., Li Y., Robinson B., et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. American Journal of Kidney Diseases. 2015;66(1, supplement 1):S1–S305. - PMC - PubMed
    1. Lopez-Vargas P. A., Tong A., Howell M., Craig J. C. Educational interventions for patients with CKD: a systematic review. American Journal of Kidney Diseases. 2015;68(3):353–370. doi: 10.1053/j.ajkd.2016.01.022. - DOI - PubMed
    1. Uhlig K., Berns J. S., Carville S., et al. Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee. Kidney International. 2016;89(4):753–760. doi: 10.1016/j.kint.2015.11.030. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources